MarketVIEW: RSV vaccines (CAT: VAMV023)

Product Name : MarketVIEW: Respiratory Syncytial Virus vaccines
Description : Global vaccine commercial opportunity assessment
Contents : Executive presentation (.pdf) + forecast model (.xls)
Therapeutic Area : Novel pediatric and elderly vaccines
Publication date : March 2016
Catalogue No : VAMV023

Background

Respiratory Syncytial Virus (RSV) is a leading cause of acute infant/childhood (< 5yrs) lower respiratory tract infections (ALRIs) and hospitalization. In particular, elderly adults and/or those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with malignancies are also at increased risk of RSV infection related complications. On a global basis, RSV is estimated to be responsible for 30 million episodes and 53,000 to 199,000 deaths per year, mostly children. 99% of deaths occur in developing countries.

An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in “at risk” groups. Currently a number of approaches are being pursued including live-attenuated viruses and/or recombinant proteins, the most advanced of which is from US biotech Novavax (RSV-F) who have recently entered Phase I/II trials with a VLP recombinant fusion protein. An adult filing is expected in 1H 2007.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new RSV vaccines across global markets¹ to 2035. The model contains value ($ m) and volume (mio doses) predictions for infants (<1yrs) and various adult target groups (maternal, elderly and “at risk”). Differing RSV vaccine profiles (infant + maternal + elderly) and related issues such as differential pricing are also discussed along with an up-to-date review of epidemiology and the competitive environment, R&D pipeline.

¹ High income, PAHO (Latin America), Asia, Middle-East, Africa (Non-GAVI) and GAVI
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to RSV epidemiology/vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of respiratory pathogens has also been utilised.

PRODUCT CONTENTS:

Published March 2016 (CAT No: VAMV023)

****This product is composed of a model (.xls) and summary presentation (.pdf)

Executive summary
Authors note
Contents
Executive summary
RSV vaccines: Commercial model - key outputs
Predicted global sales ($m) by target segment, 2015-2035
Predicted infant and maternal immunization sales ($m), 2015-2035
Predicted infant immunization sales ($m) by country/region, 2030
Predicted maternal immunization sales ($m) by country/region, 2030
Predicted elderly and at-risk immunizations sales ($m), 2015-2035
Predicted elderly immunization sales ($m), by country/region, 2030
Predicted “at-risk” immunization sales ($m), by country/region, 2030
Predicted global volume per segment (doses) to 2035
RSV vaccines: Commercial model - key assumptions
The role of RSV vaccines
RSV vaccine target populations: overview
RSV vaccine: infant target product profile (TPP)
RSV vaccine: maternal immunization target product profile (TPP)
RSV vaccine: elderly/at-risk target product profile (TPP)
Markets/regions included in model
RSV vaccine predicted uptake per country/region
Forecast comparisons: March 2016 vs. April 2014*
Pricing: infant and maternal immunization
Pricing: elderly and at-risk immunization
Pricing: elderly and at-risk immunization (cont..)
RSV vaccines: R&D pipeline
Competitor landscape: overview
Novavax: elderly immunization
Novavax: elderly immunization - Phase III
Novavax: elderly immunization - trial review
Novavax: maternal immunization
Novavax: maternal immunization - Phase II results
Novavax: maternal immunization - US seasons

---

2 Model contents are available upon request only
Continued........

Novavax: maternal immunization - Phase III
Novavax: maternal immunization - trial review
Novavax: infant immunization
GSK: maternal and infant immunization
Other companies with clinical stage RSV vaccines
RSV - review of latest epidemiology
Epidemiology: overview (3 slides)
RSV disease burden: infants
RSV disease burden: US infants
RSV disease burden: infants – hospitalizations
RSV disease burden: infants – bronchiolitis
RSV disease burden: infants – lower income countries
RSV disease burden: infants – India
RSV disease burden: infants – vaccine strategy
RSV disease burden: elderly (8 slides)
RSV disease burden: elderly – Cardiopulmonary disease
Back-up material
Methodology – populations
Methodology – vaccine uptake (14 slides)
Bibliography
About VacZine Analytics
Disclaimer

PAGES: 82 MS slides available in .pdf form
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- **USD $9995.00/ GBP £7000.00** (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total
# - indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

---

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY

2. Rotavirus vaccine to be introduced for babies. Available at: http://www.nhs.uk/news/2012/11November/Pages/New-vaccine-to-prevent-rotavirus-diarrohhea-in-babies.aspx
3. PAHO. Revolving Fund Prices. Available at: http://www.paho.org/
7. RSV Vaccine Snapshot. Available at: http://sites.path.org/vaccinedevelopment/respiratory-syncytial-virus-rsv/
8. Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults. August 2015. Available at: http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2078538
33. European Core Health Indicators. Available at: http://ec.europa.eu/health/major_chronic_diseases/indicators/index_en.htm#fragment0
34. Kein Zusatznutzen belegt für Umeclidinium/Vilanterol bei COPD. Available at: http://www.idw-online.de
42. WHO/UNICEF. Immunization Coverage. Available at: http://www.who.int/immunization/monitoring_surveillance/data/en/
43. PAHO. Influenza vaccine coverage data. Available at: http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=4048&Itemid=4210
50. MMWR. Influenza Vaccination Coverage Among Pregnant Women — United States, 2014–15 Influenza Season. September 18, 2015 / 64(36);1000-1005. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6436a2.htm
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009